3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Hepatocellular
8
Melanoma
4
Uveal Melanoma
3
Sarcoma
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Mesothelioma, Malignant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
Ichthyosis, X-Linked
1
HER2 Negative Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Cisplatin
55
Carboplatin
49
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
Sorafenib
10
Platinum
10
130-nm albumin-bound paclitaxel
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled